BBM Ltd - Better Delivery of Established Medicines (EIS approved)
Ground Breaking drug delivery device for the leading Osteoporosis drug and the Flu Vaccine
The market size for the treatment of Osteoporosis and Flu Vaccines is massive, the combined global market estimated to be worth over $20 billion by 2025.
The new device allows both drugs to be delivered via microneedles through the skin which are a less invasive, less painful, and an easier way than the current traditional injections used. Furthermore the liquid dose in the current injections needs to be kept refrigerated, whilst there is no need for refrigeration using the new device.
This technology has already successfully undergone considerable development and with the required funding to complete the necessary remaining development and trials – the device for delivering the Osteoporosis drug is expected to be ready to submit for approval by September 2020 and for the Flu Vaccine by June 2021.
The incredible thing about this investment opportunity is that in a relatively short space of time this company could have products that can generate upto $300 million of sales per year based on relatively conservative penetration levels. The return on investment potential could therefore be exponential.
BBM Ltd has licensed this revolutionary and disruptive technology for the US market from the award winning company, Nemaura Pharma (www.nemaura.co.uk).
Some key facts about Nemaura Pharma:
If you are interested, please review the investor presentation.
Micro Intelligent Diagnostics Ltd (SEIS and EIS approved)
MID is a company that has developed a detection and diagnosis technology for Urinary Tract Infections (UTI) which is more accurate and faster than current methods. Please see pdf for further information.
If you are interested in any of the above opportunities, please email email@example.com